Factors such as increasing global incidence of acute kidney injury, increasing incidence of sepsis, growing prevalence of diabetes, and hypertension are driving the growth of the market.
Disposables product segment poised to grow fastest in CRRT market
On the basis of product, the CRRT market is segmented into CRRT systems, disposables, and dialysates & replacement fluids. The disposables segment is expected to register highest CAGR during the forecast period mainly due to the large and regular demand for consumables owing to their short work life.
Continuous venovenous hemodiafiltration (CVVHDF) segment is expected to register fastest growth rate during the forecast period
Based on modality, the continuous renal replacement therapy market is segmented into slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). CVVHDF segment is projected to register the highest CAGR due to benefits of convection and diffusion for the removal of solutes (which combines filtration and dialysis processes for the removal of small to medium-sized molecules).
Europe is estimated to account for the largest share of the CRRT market
Geographically, the continuous renal replacement therapy market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is expected to grow at the highest CAGR during the forecast period due to the increasing incidence of acute kidney injuries.
The major players in continuous renal replacement therapy market are Baxter International Inc. (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), Nikkiso Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Bellco S.r.l. (Italy), NxStage Medical, Inc. (U.S.), Asahi Kasei Corporation (Japan), Infomed SA (Switzerland), Medica S.p.A. (Italy), and Toray Medical Co., Ltd. (Japan).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
